The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)

Abstract

To ensure that clinical laboratories produce results that are both accurate and of clinical utility it is essential that only samples of adequate quality are analysed. Although various studies and databases assessing the stability of analytes in different settings do exist, guidance on how to perform and report stability studies is lacking. This results in studies that often do not report essential information, thus compromising transferability of the data. The aim of this manuscript is to describe the Checklist for Reporting Stability Studies (CRESS) against which future studies should be reported to ensure standardisation of reporting and easy assessment of transferability of studies to other healthcare settings. The EFLM WG-PRE (European Federation of Clinical Chemistry and Laboratory Medicine Working Group for the Preanalytical Phase) produced the CRESS checklist following a detailed literature review and extensive discussions resulting in consensus agreement. The checklist consists of 20 items covering all the aspects that should be considered when producing a report on a stability study including details of what should be included for each item and a rationale as to why. Adherence to the CRESS checklist will ensure that studies are reported in a transparent and replicable way. This will allow other laboratories to assess whether published data meet the stability criteria required in their own particular healthcare scenario. The EFLM WG-PRE encourage researchers and authors to use the CRESS checklist as a guide to planning stability studies and to produce standardised reporting of future stability studies.

Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

“…These factors include temperature, time, tube type, and the timing of sample centrifugation. 58 The available information from manufacturers and the literature is highly variable on these issues; however, this may reflect limitations of the studies, rather than limits of stability. Variation in manufacturers' claims may be more likely to be due to differences in the studies performed than in the tube or assay type used.…”

Stability assessment of serum tumour markers: Calcitonin, chromogranin A, thyroglobulin and anti-thyroglobulin antibodies

“…Since this study, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE) has released a checklist for the reporting of stability studies, 6 including clinical details of all samples included in any pooled sample, method of phlebotomy and preanalytical sample handling, which would be utilised in any extension of this work.…”

Is canine calprotectin in serum stabile after storage at low temperature?

“…The concentration of calprotectin was 10 times higher after 16 weeks than the concentration measured after 8 weeks. Reporting of stability was done in accordance with the CRESS guidelines Moreover, the CRESS guidelines stated that the stability of a certain analyte should be determined on a minimum of 10 different samples [ 19 ].…”